1
|
Dannemeyer M, Berling A, Kanje S, Enstedt H, Xu L, Afshari D, Westin M, Hober G, Uhlén M, Hober S, Tegel H. Fast and robust recombinant protein production utilizing episomal stable pools in WAVE bioreactors. Protein Expr Purif 2024; 221:106505. [PMID: 38768672 DOI: 10.1016/j.pep.2024.106505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2024] [Revised: 05/16/2024] [Accepted: 05/17/2024] [Indexed: 05/22/2024]
Abstract
Protein reagents are essential resources for several stages of drug discovery projects from structural biology and assay development through lead optimization. Depending on the aim of the project different amounts of pure protein are required. Small-scale expressions are initially used to determine the reachable levels of production and quality before scaling up protein reagent supply. Commonly, amounts of several hundreds of milligrams to grams are needed for different experiments, including structural investigations and activity evaluations, which require rather large cultivation volumes. This implies that cultivation of large volumes of either transiently transfected cells or stable pools/stable cell lines is needed. Hence, a production process that is scalable, speeds up the development projects, and increases the robustness of protein reagent quality throughout scales. Here we present a protein production pipeline with high scalability. We show that our protocols for protein production in Chinese hamster ovary cells allow for a seamless and efficient scale-up with robust product quality and high performance. The flexible scale of the production process, as shown here, allows for shorter lead times in drug discovery projects where there is a reagent demand for a specific protein or a set of target proteins.
Collapse
Affiliation(s)
- Melanie Dannemeyer
- Department of Protein Science, School of Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, SE-10691, Stockholm, Sweden
| | - Anna Berling
- Department of Protein Science, School of Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, SE-10691, Stockholm, Sweden
| | - Sara Kanje
- Department of Protein Science, School of Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, SE-10691, Stockholm, Sweden
| | - Henric Enstedt
- Department of Protein Science, School of Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, SE-10691, Stockholm, Sweden
| | - LanLan Xu
- Department of Protein Science, School of Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, SE-10691, Stockholm, Sweden
| | - Delaram Afshari
- Department of Protein Science, School of Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, SE-10691, Stockholm, Sweden
| | - Malin Westin
- Department of Protein Science, School of Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, SE-10691, Stockholm, Sweden
| | - Gabriella Hober
- Department of Protein Science, School of Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, SE-10691, Stockholm, Sweden
| | - Mathias Uhlén
- Department of Protein Science, School of Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, SE-10691, Stockholm, Sweden
| | - Sophia Hober
- Department of Protein Science, School of Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, SE-10691, Stockholm, Sweden
| | - Hanna Tegel
- Department of Protein Science, School of Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, SE-10691, Stockholm, Sweden.
| |
Collapse
|
2
|
Yang CH, Li HC, Lo SY. Enhancing recombinant antibody yield in Chinese hamster ovary cells. Tzu Chi Med J 2024; 36:240-250. [PMID: 38993821 PMCID: PMC11236083 DOI: 10.4103/tcmj.tcmj_315_23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2023] [Revised: 03/18/2024] [Accepted: 04/12/2024] [Indexed: 07/13/2024] Open
Abstract
A range of recombinant monoclonal antibodies (rMAbs) have found application in treating diverse diseases, spanning various cancers and immune system disorders. Chinese hamster ovary (CHO) cells have emerged as the predominant choice for producing these rMAbs due to their robustness, ease of transfection, and capacity for posttranslational modifications akin to those in human cells. Transient transfection and/or stable expression could be conducted to express rMAbs in CHO cells. To bolster the yield of rMAbs in CHO cells, a multitude of approaches have been developed, encompassing vector optimization, medium formulation, cultivation parameters, and cell engineering. This review succinctly outlines these methodologies when also addressing challenges encountered in the production process, such as issues with aggregation and fucosylation.
Collapse
Affiliation(s)
- Chee-Hing Yang
- Department of Microbiology and Immunology, School of Medicine, Tzu Chi University, Hualien, Taiwan
| | - Hui-Chun Li
- Department of Biochemistry, School of Medicine, Tzu Chi University, Hualien, Taiwan
| | - Shih-Yen Lo
- Department of Laboratory Medicine and Biotechnology, Tzu Chi University, Hualien, Taiwan
- Department of Laboratory Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical, Hualien, Taiwan
| |
Collapse
|
3
|
Tang X, Quiroz J, Zhang Y, Pan J, Lai Z, Du Z, Liu R. A deep-well plate enabled automated high-throughput cell line development platform. Biotechnol Prog 2024; 40:e3442. [PMID: 38377061 DOI: 10.1002/btpr.3442] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2023] [Revised: 12/28/2023] [Accepted: 01/26/2024] [Indexed: 02/22/2024]
Abstract
Cell line development (CLD) plays a crucial role in the manufacturing process development of therapeutic biologics. Most biologics are produced in Chinese hamster ovary (CHO) cell. Because of the nature of random transgene integration in CHO genome and CHO's inherent plasticity, stable CHO transfectants usually have a vast diversity in productivity, growth, and product quality. Thus, we often must resort to screening a large number of cell pools and clones to increase the probability of identifying the ideal production cell line, which is a very laborious and resource-demanding process. Here we have developed a deep-well plate (DWP) enabled high throughput (DEHT) CLD platform using 24-well DWP (24DWP), liquid handler, and other automation components. This platform has capabilities covering the key steps of CLD including cell passaging, clone imaging and expansion, and fed-batch production. We are the first to demonstrate the suitability of 24DWP for CLD by confirming minimal well-to-well and plate-to-plate variability and the absence of well-to-well cross contamination. We also demonstrated that growth, production, and product quality of 24DWP cultures were comparable to those of conventional shake flask cultures. The DEHT platform enables scientists to screen five times more cultures than the conventional CLD platform, thus significantly decreases the resources needed to identify an ideal production cell line for biologics manufacturing.
Collapse
Affiliation(s)
- Xiaoyan Tang
- Process Cell Sciences, MRL, Merck & Co., Inc., Rahway, New Jersey, USA
| | - Jorge Quiroz
- BARDS, Research CMC Statistics, Merck & Co., Inc., Rahway, New Jersey, USA
| | - Yixiao Zhang
- Process Cell Sciences, MRL, Merck & Co., Inc., Rahway, New Jersey, USA
| | - Jessica Pan
- Process Cell Sciences, MRL, Merck & Co., Inc., Rahway, New Jersey, USA
| | - Zhong Lai
- BARDS, Research CMC Statistics, Merck & Co., Inc., Rahway, New Jersey, USA
| | - Zhimei Du
- Process Cell Sciences, MRL, Merck & Co., Inc., Rahway, New Jersey, USA
| | - Ren Liu
- Process Cell Sciences, MRL, Merck & Co., Inc., Rahway, New Jersey, USA
| |
Collapse
|
4
|
Gunnarsson J, Fisher DI, Roth RG. Protein Expression via Transient Transfection of Mammalian Cells in a WAVE Bioreactor. Methods Mol Biol 2024; 2810:75-83. [PMID: 38926273 DOI: 10.1007/978-1-0716-3878-1_5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/28/2024]
Abstract
Large culture volumes are often required when expression constructs are particularly low-yielding or when end uses require significant amounts of material. In these cases, a single homogeneous culture is usually more convenient, in terms of both consistency of expression and labor/resource requirements, than multiple parallel cultures. Using a WAVE Bioreactor culture, volumes as high as 500L may be achieved in a single vessel. Here, we describe the transfection of Expi293F cells in a disposable 50L Cellbag on a WAVE Bioreactor platform to produce recombinant protein. The methods described herein may be adapted, with suitable optimizations, for other suspension-adapted mammalian cell lines.
Collapse
Affiliation(s)
- Jenny Gunnarsson
- Discovery Biology, Discovery Sciences, BioPharmaceutical R&D, AstraZeneca, Gothenburg, Sweden.
| | - David I Fisher
- Discovery Biology, Discovery Sciences, BioPharmaceutical R&D, AstraZeneca, Cambridge, UK
| | - Robert G Roth
- Discovery Biology, Discovery Sciences, BioPharmaceutical R&D, AstraZeneca, Gothenburg, Sweden
| |
Collapse
|
5
|
Schmitt MG, White RN, Barnard GC. Development of a high cell density transient CHO platform yielding mAb titers greater than 2 g/L in only 7 days. Biotechnol Prog 2021; 36:e3047. [PMID: 33411420 DOI: 10.1002/btpr.3047] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2020] [Revised: 07/06/2020] [Accepted: 07/08/2020] [Indexed: 12/21/2022]
Abstract
We developed a simple transient Chinese Hamster Ovary expression platform. Titers for a random panel of 20 clinical monoclonal antibodies (mAbs) ranged from 0.6 to 2.7 g/L after 7 days. Two factors were the key in obtaining these high titers. First, we utilized an extremely high starting cell density (20 million cells/ml), and then arrested further cell growth by employing mild hypothermic conditions (32°C). Second, we performed a 6-variable Design of Experiments to find optimal concentrations of plasmid DNA (coding DNA), boost DNA (DNA encoding the XBP1S transcription factor), transfection reagent (polyethylenimine [PEI]), and nutrient feed amounts. High coding DNA concentrations (12.5 mg/L) were found to be optimal. We therefore diluted expensive coding DNA with inexpensive inert filler DNA (herring sperm DNA). Reducing the coding DNA concentration by 70% from 12.5 to 3.75 mg/L did not meaningfully reduce mAb titers. Titers for the same panel of 20 clinical mAbs ranged from 0.7 to 2.2 g/L after reducing the coding DNA concentration to 3.75 mg/L. Finally, we found that titer and product quality attributes were similar for a clinical mAb (rituximab) expressed at very different scales (volumes ranging from 3 ml to 2 L).
Collapse
Affiliation(s)
- Matthew G Schmitt
- Biotechnology Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Lilly Technology Center, Indianapolis, Indiana, USA
| | - Regina N White
- Biotechnology Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Lilly Technology Center, Indianapolis, Indiana, USA
| | - Gavin C Barnard
- Biotechnology Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Lilly Technology Center, Indianapolis, Indiana, USA
| |
Collapse
|
6
|
Elshereef AA, Jochums A, Lavrentieva A, Stuckenberg L, Scheper T, Solle D. High cell density transient transfection of CHO cells for TGF-β1 expression. Eng Life Sci 2020; 19:730-740. [PMID: 32624966 DOI: 10.1002/elsc.201800174] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2018] [Revised: 07/30/2019] [Accepted: 08/20/2019] [Indexed: 01/08/2023] Open
Abstract
High cell densities for transient transfection with polyethyleneimine (PEI) can be used for rapid and maximal production of recombinant proteins. High cell densities can be obtained by different cultivation systems, such as batch or perfusion systems. Herein, densities up to 18 million cells/mL were obtained by centrifugation for transfection evaluation. PEI transfection efficiency was easily determined by transfected enhanced green fluorescence protein (EGFP) reporter plasmid DNA (pDNA). A linear correlation between fluorescence intensity and transfection efficiency was improved. The transfection efficiency of PEI was highly dependent on the transfection conditions and directly related to the level of recombinant protein. Several factors were required to optimize the transient transfection process; these factors included the media type (which is compatible with low or high cell density transfection), the preculture CHO-K1 suspension cell density, and the pDNA to PEI level. Based on design of experiment (DoE) analyses, the optimal transfection conditions for 10 × 106 cells/mL in the CHOMACS CD medium achieved 73% transfection efficiency and a cell viability of over 80%. These results were confirmed for the production of transforming growth factor-beta 1 (TGF-β1) in a shake flask. The purified TGF-β1 protein concentration from 60 mL supernatant was 27 µg/mL, and the protein was biologically active.
Collapse
Affiliation(s)
- Abdalla A Elshereef
- Institute of Technical Chemistry Gottfried Wilhelm Leibniz University of Hannover Hannover Germany.,Chemistry of Natural and Microbial Products Department Pharmaceutical and Drug Industries Research Division National Research Centre Giza Egypt
| | - André Jochums
- Institute of Technical Chemistry Gottfried Wilhelm Leibniz University of Hannover Hannover Germany
| | - Antonina Lavrentieva
- Institute of Technical Chemistry Gottfried Wilhelm Leibniz University of Hannover Hannover Germany
| | - Lena Stuckenberg
- Institute of Technical Chemistry Gottfried Wilhelm Leibniz University of Hannover Hannover Germany
| | - Thomas Scheper
- Institute of Technical Chemistry Gottfried Wilhelm Leibniz University of Hannover Hannover Germany
| | - Dörte Solle
- Institute of Technical Chemistry Gottfried Wilhelm Leibniz University of Hannover Hannover Germany
| |
Collapse
|
7
|
A platform for context-specific genetic engineering of recombinant protein production by CHO cells. J Biotechnol 2020; 312:11-22. [DOI: 10.1016/j.jbiotec.2020.02.012] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2019] [Revised: 12/12/2019] [Accepted: 02/25/2020] [Indexed: 12/12/2022]
|
8
|
Luptak J, Bista M, Fisher D, Flavell L, Gao N, Wickson K, Kazmirski SL, Howard T, Rawlins PB, Hargreaves D. Antibody fragments structurally enable a drug-discovery campaign on the cancer target Mcl-1. Acta Crystallogr D Struct Biol 2019; 75:1003-1014. [PMID: 31692474 PMCID: PMC6834078 DOI: 10.1107/s2059798319014116] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2019] [Accepted: 10/16/2019] [Indexed: 11/23/2022] Open
Abstract
Apoptosis is a crucial process by which multicellular organisms control tissue growth, removal and inflammation. Disruption of the normal apoptotic function is often observed in cancer, where cell death is avoided by the overexpression of anti-apoptotic proteins of the Bcl-2 (B-cell lymphoma 2) family, including Mcl-1 (myeloid cell leukaemia 1). This makes Mcl-1 a potential target for drug therapy, through which normal apoptosis may be restored by inhibiting the protective function of Mcl-1. Here, the discovery and biophysical properties of an anti-Mcl-1 antibody fragment are described and the utility of both the scFv and Fab are demonstrated in generating an Mcl-1 crystal system amenable to iterative structure-guided drug design.
Collapse
Affiliation(s)
- Jakub Luptak
- Discovery Sciences, R&D Biopharmaceuticals, AstraZeneca, Cambridge CB4 0WG, England
| | - Michal Bista
- Discovery Sciences, R&D Biopharmaceuticals, AstraZeneca, Cambridge CB4 0WG, England
| | - David Fisher
- Discovery Sciences, R&D Biopharmaceuticals, AstraZeneca, Cambridge CB4 0WG, England
| | - Liz Flavell
- Discovery Sciences, R&D Biopharmaceuticals, AstraZeneca, Cambridge CB4 0WG, England
| | - Ning Gao
- Discovery Sciences, R&D Biopharmaceuticals, AstraZeneca, Waltham, MA 02451, USA
| | - Kate Wickson
- Discovery Sciences, R&D Biopharmaceuticals, AstraZeneca, Cambridge CB4 0WG, England
| | - Steven L. Kazmirski
- Discovery Sciences, R&D Biopharmaceuticals, AstraZeneca, Waltham, MA 02451, USA
| | - Tina Howard
- Discovery Sciences, R&D Biopharmaceuticals, AstraZeneca, Cambridge CB4 0WG, England
| | - Philip B. Rawlins
- Discovery Sciences, R&D Biopharmaceuticals, AstraZeneca, Cambridge CB4 0WG, England
| | - David Hargreaves
- Discovery Sciences, R&D Biopharmaceuticals, AstraZeneca, Cambridge CB4 0WG, England
| |
Collapse
|
9
|
Construction strategies for developing expression vectors for recombinant monoclonal antibody production in CHO cells. Mol Biol Rep 2018; 45:2907-2912. [PMID: 30191354 DOI: 10.1007/s11033-018-4351-0] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2018] [Accepted: 08/16/2018] [Indexed: 12/16/2022]
Abstract
Recent years have seen the use of recombinant proteins in the treatment of different diseases. Among them, monoclonal antibodies (mAbs) are currently the fastest growing class of bio-therapeutic recombinant proteins. Chinese hamster ovary (CHO) cells are the most commonly used host cells for production of these recombinant mAbs. Expression vectors determine the expression level and quality of recombinant mAbs. Currently, few construction strategies for recombinant mAbs expression vectors in CHO cells have been developed, including monocistronic vector, multiple-promoter expression vector, and tricistronic vector mediated by internal ribosome entry site (IRES) or Furin-2A element. Among them, Furin-2A-mediated vector is an effective approach due to advantages of high "self-cleavage" efficiency, and equal expression of light and heavy chains from a single open reading frame. Here, we have reviewed the progress in development of different strategies for constructing recombinant mAb expression vectors in CHO cells and its potential advantages and disadvantages.
Collapse
|
10
|
Hussain H, Fisher DI, Roth RG, Mark Abbott W, Carballo-Amador MA, Warwicker J, Dickson AJ. A protein chimera strategy supports production of a model "difficult-to-express" recombinant target. FEBS Lett 2018; 592:2499-2511. [PMID: 29933498 PMCID: PMC6174982 DOI: 10.1002/1873-3468.13170] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2018] [Revised: 06/05/2018] [Accepted: 06/11/2018] [Indexed: 12/30/2022]
Abstract
Due in part to the needs of the biopharmaceutical industry, there has been an increased drive to generate high quality recombinant proteins in large amounts. However, achieving high yields can be a challenge as the novelty and increased complexity of new targets often makes them 'difficult-to-express'. This study aimed to define the molecular features that restrict the production of a model 'difficult-to-express' recombinant protein, Tissue Inhibitor Metalloproteinase-3 (TIMP-3). Building from experimental data, computational approaches were used to rationalize the redesign of this recombinant target to generate a chimera with enhanced secretion. The results highlight the importance of early identification of unfavourable sequence attributes, enabling the generation of engineered protein forms that bypass 'secretory' bottlenecks and result in efficient recombinant protein production.
Collapse
Affiliation(s)
- Hirra Hussain
- Faculty of Science and Engineering, Manchester Institute of Biotechnology, University of Manchester, UK
| | - David I Fisher
- Discovery Biology, Discovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, UK
| | - Robert G Roth
- Discovery Biology, Discovery Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden
| | - W Mark Abbott
- Discovery Biology, Discovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, UK
| | | | - Jim Warwicker
- Faculty of Science and Engineering, Manchester Institute of Biotechnology, University of Manchester, UK
| | - Alan J Dickson
- Faculty of Science and Engineering, Manchester Institute of Biotechnology, University of Manchester, UK
| |
Collapse
|
11
|
Stuible M, Burlacu A, Perret S, Brochu D, Paul-Roc B, Baardsnes J, Loignon M, Grazzini E, Durocher Y. Optimization of a high-cell-density polyethylenimine transfection method for rapid protein production in CHO-EBNA1 cells. J Biotechnol 2018; 281:39-47. [PMID: 29886030 DOI: 10.1016/j.jbiotec.2018.06.307] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2018] [Revised: 05/23/2018] [Accepted: 06/06/2018] [Indexed: 12/12/2022]
Abstract
For pre-clinical evaluation of biotherapeutic candidates, protein production by transient gene expression (TGE) in Chinese Hamster Ovary (CHO) cells offers important advantages, including the capability of rapidly and cost-effectively generating recombinant proteins that are highly similar to those produced in stable CHO clones. We have established a novel CHO clone (CHO-3E7) expressing a form of the Epstein-Barr virus nuclear antigen-1 (EBNA-1) with improved TGE productivity relative to parental CHO cells. Taking advantage of a new transfection-compatible media formulation that permits prolonged, high-density culture, we optimized transfection parameters (cell density, plasmid vector and polyethylenimine concentrations) and post-transfection culture conditions to establish a new, high-performing process for rapid protein production. The growth media is chemically defined, and a single hydrolysate feed is added post-transfection, followed by periodic glucose supplementation. This method gave significantly higher yields than our standard low-cell density, F17-based CHO-3E7 TGE method, averaging several hundred mg/l for a panel of recombinant proteins and antibodies. Purified antibodies produced using the two methods had distinct glycosylation profiles but showed identical target binding kinetics by SPR. Key advantages of this new protein production platform include the cost-effectiveness of the transfection reagent, the commercial availability of the culture media and the ability to perform high-cell-density transfection without media change.
Collapse
Affiliation(s)
- Matthew Stuible
- Human Health Therapeutics Research Centre, National Research Council Canada, 6100 Royalmount, Montreal, QC, H4P 2R2, Canada
| | - Alina Burlacu
- Human Health Therapeutics Research Centre, National Research Council Canada, 6100 Royalmount, Montreal, QC, H4P 2R2, Canada
| | - Sylvie Perret
- Human Health Therapeutics Research Centre, National Research Council Canada, 6100 Royalmount, Montreal, QC, H4P 2R2, Canada
| | - Denis Brochu
- Human Health Therapeutics Research Centre, National Research Council Canada, 6100 Royalmount, Montreal, QC, H4P 2R2, Canada
| | - Béatrice Paul-Roc
- Human Health Therapeutics Research Centre, National Research Council Canada, 6100 Royalmount, Montreal, QC, H4P 2R2, Canada
| | - Jason Baardsnes
- Human Health Therapeutics Research Centre, National Research Council Canada, 6100 Royalmount, Montreal, QC, H4P 2R2, Canada
| | - Martin Loignon
- Human Health Therapeutics Research Centre, National Research Council Canada, 6100 Royalmount, Montreal, QC, H4P 2R2, Canada
| | - Eric Grazzini
- Human Health Therapeutics Research Centre, National Research Council Canada, 6100 Royalmount, Montreal, QC, H4P 2R2, Canada
| | - Yves Durocher
- Human Health Therapeutics Research Centre, National Research Council Canada, 6100 Royalmount, Montreal, QC, H4P 2R2, Canada.
| |
Collapse
|
12
|
McKenzie EA, Abbott WM. Expression of recombinant proteins in insect and mammalian cells. Methods 2018; 147:40-49. [PMID: 29778647 DOI: 10.1016/j.ymeth.2018.05.013] [Citation(s) in RCA: 45] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2018] [Revised: 05/10/2018] [Accepted: 05/15/2018] [Indexed: 12/12/2022] Open
Abstract
Purified recombinant proteins are key reagents in academic and industrial research. The ability to make these proteins quickly often relies on the availability of higher eukaryotic cell hosts such as insect and mammalian cells where there is a very wide range of post-translational modifications, protein folding and trafficking pathways. This enables the generation of many proteins that cannot be made in microbial hosts. In this article we outline some of the most commonly used methods to express recombinant proteins in insect and mammalian cells.
Collapse
Affiliation(s)
- Edward A McKenzie
- Protein Expression Facility, Manchester Institute of Biotechnology, Faculty of Life Sciences, 131 Princess Street, Manchester M1 7DN, UK
| | - W Mark Abbott
- Peak Proteins Ltd, Alderley Park, Cheshire SK10 4TG, UK.
| |
Collapse
|
13
|
Bayat H, Hossienzadeh S, Pourmaleki E, Ahani R, Rahimpour A. Evaluation of different vector design strategies for the expression of recombinant monoclonal antibody in CHO cells. Prep Biochem Biotechnol 2018; 48:160-164. [DOI: 10.1080/10826068.2017.1421966] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- Hadi Bayat
- Medical Nano-Technology and Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Saghar Hossienzadeh
- Medical Nano-Technology and Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Eśhagh Pourmaleki
- Medical Nano-Technology and Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Roshanak Ahani
- Department of Virology, Pasteur Institute of Iran, Tehran, Iran
| | - Azam Rahimpour
- Medical Nano-Technology and Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| |
Collapse
|
14
|
Gutiérrez-Granados S, Cervera L, Kamen AA, Gòdia F. Advancements in mammalian cell transient gene expression (TGE) technology for accelerated production of biologics. Crit Rev Biotechnol 2018; 38:918-940. [DOI: 10.1080/07388551.2017.1419459] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- Sonia Gutiérrez-Granados
- Departament d’Enginyeria Química, Biològica i Ambiental, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Laura Cervera
- Department of Bioengineering, McGill University, Montréal, Canada
| | - Amine A. Kamen
- Department of Bioengineering, McGill University, Montréal, Canada
| | - Francesc Gòdia
- Departament d’Enginyeria Química, Biològica i Ambiental, Universitat Autònoma de Barcelona, Barcelona, Spain
| |
Collapse
|
15
|
L'Abbé D, Bisson L, Gervais C, Grazzini E, Durocher Y. Transient Gene Expression in Suspension HEK293-EBNA1 Cells. Methods Mol Biol 2018; 1850:1-16. [PMID: 30242676 DOI: 10.1007/978-1-4939-8730-6_1] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
Transient gene expression in human embryo kidney 293 (HEK293) cells is an established approach for the rapid production of large amounts of recombinant proteins (r-proteins). Milligram to gram quantities of r-proteins can be typically obtained within less than 10 days following transfection. In this chapter, we describe a simple and robust transfection process of suspension-growing human embryo kidney 293 cells using two commercially available serum-free media and polyethylenimine as the transfection reagent. This chapter provides examples for the production and purification of a his-tagged recombinant protein and two monoclonal antibodies.
Collapse
Affiliation(s)
- Denis L'Abbé
- Human Health Therapeutics Research Center, National Research Council Canada, 6100 Royalmount Avenue, Montreal, H4P 2R2, Quebec, Canada
| | - Louis Bisson
- Human Health Therapeutics Research Center, National Research Council Canada, 6100 Royalmount Avenue, Montreal, H4P 2R2, Quebec, Canada
| | - Christian Gervais
- Human Health Therapeutics Research Center, National Research Council Canada, 6100 Royalmount Avenue, Montreal, H4P 2R2, Quebec, Canada
| | - Eric Grazzini
- Human Health Therapeutics Research Center, National Research Council Canada, 6100 Royalmount Avenue, Montreal, H4P 2R2, Quebec, Canada
| | - Yves Durocher
- Human Health Therapeutics Research Center, National Research Council Canada, 6100 Royalmount Avenue, Montreal, H4P 2R2, Quebec, Canada.
| |
Collapse
|
16
|
Production of HIV virus-like particles by transient transfection of CAP-T cells at bioreactor scale avoiding medium replacement. J Biotechnol 2017; 263:11-20. [DOI: 10.1016/j.jbiotec.2017.09.019] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2017] [Revised: 09/25/2017] [Accepted: 09/27/2017] [Indexed: 11/20/2022]
|
17
|
Mora A, Zhang SS, Carson G, Nabiswa B, Hossler P, Yoon S. Sustaining an efficient and effective CHO cell line development platform by incorporation of 24-deep well plate screening and multivariate analysis. Biotechnol Prog 2017; 34:175-186. [DOI: 10.1002/btpr.2584] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2017] [Revised: 11/05/2017] [Indexed: 12/31/2022]
Affiliation(s)
- Alessandro Mora
- Cell Line Development, Process Sciences Dept.; AbbVie Bioresearch Center; Worcester MA
- Francis College of Engineering; University of Massachusetts Lowell; Lowell MA
| | - Sheng Sam Zhang
- Cell Line Development, Process Sciences Dept.; AbbVie Bioresearch Center; Worcester MA
| | - Gerald Carson
- Cell Line Development, Process Sciences Dept.; AbbVie Bioresearch Center; Worcester MA
| | - Bernard Nabiswa
- Cell Line Development, Process Sciences Dept.; AbbVie Bioresearch Center; Worcester MA
| | - Patrick Hossler
- Cell Culture, Process Sciences Dept.; AbbVie Bioresearch Center; Worcester MA
| | - Seongkyu Yoon
- Francis College of Engineering; University of Massachusetts Lowell; Lowell MA
| |
Collapse
|
18
|
Agez M, Schultz P, Medina I, Baker DJ, Burnham MP, Cardarelli RA, Conway LC, Garnier K, Geschwindner S, Gunnarsson A, McCall EJ, Frechard A, Audebert S, Deeb TZ, Moss SJ, Brandon NJ, Wang Q, Dekker N, Jawhari A. Molecular architecture of potassium chloride co-transporter KCC2. Sci Rep 2017; 7:16452. [PMID: 29184062 PMCID: PMC5705597 DOI: 10.1038/s41598-017-15739-1] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2017] [Accepted: 10/27/2017] [Indexed: 01/15/2023] Open
Abstract
KCC2 is a neuron specific K+-Cl− co-transporter that controls neuronal chloride homeostasis, and is critically involved in many neurological diseases including brain trauma, epilepsies, autism and schizophrenia. Despite significant accumulating data on the biology and electrophysiological properties of KCC2, structure-function relationships remain poorly understood. Here we used calixarene detergent to solubilize and purify wild-type non-aggregated and homogenous KCC2. Specific binding of inhibitor compound VU0463271 was demonstrated using surface plasmon resonance (SPR). Mass spectrometry revealed glycosylations and phosphorylations as expected from functional KCC2. We show by electron microscopy (EM) that KCC2 exists as monomers and dimers in solution. Monomers are organized into “head” and “core” domains connected by a flexible “linker”. Dimers are asymmetrical and display a bent “S-shape” architecture made of four distinct domains and a flexible dimerization interface. Chemical crosslinking in reducing conditions shows that disulfide bridges are involved in KCC2 dimerization. Moreover, we show that adding a tag to the C-terminus is detrimental to KCC2 function. We postulate that the conserved KCC2 C-ter may be at the interface of dimerization. Taken together, our findings highlight the flexible multi-domain structure of KCC2 with variable anchoring points at the dimerization interface and an important C-ter extremity providing the first in-depth functional architecture of KCC2.
Collapse
Affiliation(s)
- Morgane Agez
- CALIXAR, 60 avenue Rockefeller, 69008, Lyon, France
| | - Patrick Schultz
- Department of Integrated Structural Biology, IGBMC (Institut de Génétique et de Biologie Moléculaire et Cellulaire) INSERM, U964; CNRS/Strasbourg University, UMR7104 1, rue Laurent Fries, BP10142, 67404, Illkirch, France
| | | | - David J Baker
- Discovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, UK
| | - Matthew P Burnham
- Discovery Sciences, IMED Biotech Unit, AstraZeneca, Alderley Park, UK
| | - Ross A Cardarelli
- AstraZeneca Tufts Laboratory for Basic and Translational Neuroscience, Boston, Massachusetts, 02111, USA
| | - Leslie C Conway
- AstraZeneca Tufts Laboratory for Basic and Translational Neuroscience, Boston, Massachusetts, 02111, USA
| | | | | | - Anders Gunnarsson
- Discovery Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden
| | - Eileen J McCall
- Discovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, UK
| | - Alexandre Frechard
- Department of Integrated Structural Biology, IGBMC (Institut de Génétique et de Biologie Moléculaire et Cellulaire) INSERM, U964; CNRS/Strasbourg University, UMR7104 1, rue Laurent Fries, BP10142, 67404, Illkirch, France
| | - Stéphane Audebert
- Aix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille Protéomique, Marseille, France
| | - Tarek Z Deeb
- AstraZeneca Tufts Laboratory for Basic and Translational Neuroscience, Boston, Massachusetts, 02111, USA
| | - Stephen J Moss
- Department of Neuroscience, Tufts University School of Medicine, Boston, MA, 02111, USA.,Department of Neuroscience, Physiology and Pharmacology, University College, London, WC1E, 6BT, UK
| | - Nicholas J Brandon
- AstraZeneca Tufts Laboratory for Basic and Translational Neuroscience, Boston, Massachusetts, 02111, USA.,Neuroscience, IMED Biotech Unit, AstraZeneca, Boston, MA, USA
| | - Qi Wang
- AstraZeneca Tufts Laboratory for Basic and Translational Neuroscience, Boston, Massachusetts, 02111, USA.,Neuroscience, IMED Biotech Unit, AstraZeneca, Boston, MA, USA
| | - Niek Dekker
- Discovery Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
| | - Anass Jawhari
- CALIXAR, 60 avenue Rockefeller, 69008, Lyon, France.
| |
Collapse
|
19
|
Brown AJ, Kalsi D, Fernandez-Martell A, Cartwright J, Barber NOW, Patel YD, Turner R, Bryant CL, Johari YB, James DC. Expression Systems for Recombinant Biopharmaceutical Production by Mammalian Cells in Culture. METHODS AND PRINCIPLES IN MEDICINAL CHEMISTRY 2017. [DOI: 10.1002/9783527699124.ch13] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Affiliation(s)
- Adam J. Brown
- University of Sheffield; Department of Chemical and Biological Engineering; Mappin St. Sheffield S1 3JD UK
| | - Devika Kalsi
- University of Sheffield; Department of Chemical and Biological Engineering; Mappin St. Sheffield S1 3JD UK
| | | | - Joe Cartwright
- University of Sheffield; Department of Chemical and Biological Engineering; Mappin St. Sheffield S1 3JD UK
| | - Nicholas O. W. Barber
- University of Sheffield; Department of Chemical and Biological Engineering; Mappin St. Sheffield S1 3JD UK
| | - Yash D. Patel
- University of Sheffield; Department of Chemical and Biological Engineering; Mappin St. Sheffield S1 3JD UK
| | | | - Claire L. Bryant
- University of Sheffield; Department of Chemical and Biological Engineering; Mappin St. Sheffield S1 3JD UK
| | - Yusuf B. Johari
- University of Sheffield; Department of Chemical and Biological Engineering; Mappin St. Sheffield S1 3JD UK
| | - David C. James
- University of Sheffield; Department of Chemical and Biological Engineering; Mappin St. Sheffield S1 3JD UK
| |
Collapse
|
20
|
Hussain H, Fisher DI, Abbott WM, Roth RG, Dickson AJ. Use of a protein engineering strategy to overcome limitations in the production of “Difficult to Express” recombinant proteins. Biotechnol Bioeng 2017. [DOI: 10.1002/bit.26358] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- Hirra Hussain
- Manchester Institute of Biotechnology; Faculty of Science and Engineering; University of Manchester; M1 7DN Manchester United Kingdom
| | - David I. Fisher
- AstraZeneca, Cambridge Science Park; Milton Cambridge United Kingdom
| | - W. Mark Abbott
- AstraZeneca, Cambridge Science Park; Milton Cambridge United Kingdom
| | | | - Alan J. Dickson
- Manchester Institute of Biotechnology; Faculty of Science and Engineering; University of Manchester; M1 7DN Manchester United Kingdom
| |
Collapse
|
21
|
Gulce Iz S, Inevi MA, Metiner PS, Tamis DA, Kisbet N. A BioDesign Approach to Obtain High Yields of Biosimilars by Anti-apoptotic Cell Engineering: a Case Study to Increase the Production Yield of Anti-TNF Alpha Producing Recombinant CHO Cells. Appl Biochem Biotechnol 2017; 184:303-322. [PMID: 28685239 DOI: 10.1007/s12010-017-2540-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2017] [Accepted: 06/14/2017] [Indexed: 10/19/2022]
Abstract
Recent developments in medical biotechnology have facilitated to enhance the production of monoclonal antibodies (mAbs) and recombinant proteins in mammalian cells. Human mAbs for clinical applications have focused on three areas, particularly cancer, immunological disorders, and infectious diseases. Tumor necrosis factor alpha (TNF-α), which has both proinflammatory and immunoregulatory functions, is an important target in biopharmaceutical industry. In this study, a humanized anti-TNF-α mAb producing stable CHO cell line which produces a biosimilar of Humira (adalimumab) was used. Adalimumab is a fully human anti-TNF mAb among the top-selling mAb products in recent years as a biosimilar. Products from mammalian cell bioprocesses are a derivative of cell viability and metabolism, which is mainly disrupted by cell death in bioreactors. Thus, different strategies are used to increase the product yield. Suppression of apoptosis, also called anti-apoptotic cell engineering, is the most remarkable strategy to enhance lifetime of cells for a longer production period. In fact, using anti-apoptotic cell engineering as a BioDesign approach was inspired by nature; nature gives prolonged life span to some cells like stem cells, tumor cells, and memory B and T cells, and researchers have been using this strategy for different purposes. In this study, as a biomimicry approach, anti-apoptotic cell engineering was used to increase the anti-TNF-α mAb production from the humanized anti-TNF-α mAb producing stable CHO cell line by Bcl-xL anti-apoptotic protein. It was shown that transient transfection of CHO cells by the Bcl-xL anti-apoptotic protein expressing plasmid prolonged the cell survival rate and protected cells from apoptosis. The transient expression of Bcl-xL using CHO cells enhanced the anti-TNF-α production. The production of anti-TNF-α in CHO cells was increased up to 215 mg/L with an increase of 160% after cells were transfected with Bcl-xL expressing plasmid with polyethylenimine (PEI) reagent at the ratio of 1:6 (DNA:PEI). In conclusion, the anti-apoptotic efficacy of the Bcl-xL expressing plasmid in humanized anti-TNF-α MAb producing stable CHO cells is compatible with curative effect for high efficiency recombinant protein production. Thus, this model can be used for large-scale production of biosimilars through transient Bcl-xL gene expression as a cost-effective method.
Collapse
Affiliation(s)
- Sultan Gulce Iz
- Department of Bioengineering, Faculty of Engineering, Ege University, 35100, Izmir, Bornova, Turkey.
| | - Muge Anil Inevi
- Department of Bioengineering, Faculty of Engineering, Ege University, 35100, Izmir, Bornova, Turkey
- Department of Biotechnology and Bioengineering, Izmir Institute of Technology, 35430, Izmir, Urla, Turkey
| | - Pelin Saglam Metiner
- Department of Bioengineering, Faculty of Engineering, Ege University, 35100, Izmir, Bornova, Turkey
| | - Duygu Ayyildiz Tamis
- Department of Bioengineering, Faculty of Engineering, Ege University, 35100, Izmir, Bornova, Turkey
- Turgut Ilaclari A.S, 34394, Istanbul, Besiktas, Turkey
| | - Nazli Kisbet
- Department of Bioengineering, Faculty of Engineering, Ege University, 35100, Izmir, Bornova, Turkey
- GlaxoSmithKline, 34394, Istanbul, Besiktas, Turkey
| |
Collapse
|
22
|
Baretić D, Pollard HK, Fisher DI, Johnson CM, Santhanam B, Truman CM, Kouba T, Fersht AR, Phillips C, Williams RL. Structures of closed and open conformations of dimeric human ATM. SCIENCE ADVANCES 2017; 3:e1700933. [PMID: 28508083 PMCID: PMC5425235 DOI: 10.1126/sciadv.1700933] [Citation(s) in RCA: 81] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/20/2017] [Accepted: 04/19/2017] [Indexed: 05/31/2023]
Abstract
ATM (ataxia-telangiectasia mutated) is a phosphatidylinositol 3-kinase-related protein kinase (PIKK) best known for its role in DNA damage response. ATM also functions in oxidative stress response, insulin signaling, and neurogenesis. Our electron cryomicroscopy (cryo-EM) suggests that human ATM is in a dynamic equilibrium between closed and open dimers. In the closed state, the PIKK regulatory domain blocks the peptide substrate-binding site, suggesting that this conformation may represent an inactive or basally active enzyme. The active site is held in this closed conformation by interaction with a long helical hairpin in the TRD3 (tetratricopeptide repeats domain 3) domain of the symmetry-related molecule. The open dimer has two protomers with only a limited contact interface, and it lacks the intermolecular interactions that block the peptide-binding site in the closed dimer. This suggests that the open conformation may be more active. The ATM structure shows the detailed topology of the regulator-interacting N-terminal helical solenoid. The ATM conformational dynamics shown by the structures represent an important step in understanding the enzyme regulation.
Collapse
Affiliation(s)
- Domagoj Baretić
- Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, UK
| | - Hannah K. Pollard
- Discovery Sciences, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Darwin Building, Cambridge CB4 0WG, UK
| | - David I. Fisher
- Discovery Sciences, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Darwin Building, Cambridge CB4 0WG, UK
| | | | - Balaji Santhanam
- Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, UK
| | - Caroline M. Truman
- Discovery Sciences, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Darwin Building, Cambridge CB4 0WG, UK
| | - Tomas Kouba
- Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, UK
| | - Alan R. Fersht
- Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, UK
| | - Christopher Phillips
- Discovery Sciences, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Darwin Building, Cambridge CB4 0WG, UK
| | - Roger L. Williams
- Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, UK
| |
Collapse
|
23
|
Legastelois I, Buffin S, Peubez I, Mignon C, Sodoyer R, Werle B. Non-conventional expression systems for the production of vaccine proteins and immunotherapeutic molecules. Hum Vaccin Immunother 2016; 13:947-961. [PMID: 27905833 DOI: 10.1080/21645515.2016.1260795] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
The increasing demand for recombinant vaccine antigens or immunotherapeutic molecules calls into question the universality of current protein expression systems. Vaccine production can require relatively low amounts of expressed materials, but represents an extremely diverse category consisting of different target antigens with marked structural differences. In contrast, monoclonal antibodies, by definition share key molecular characteristics and require a production system capable of very large outputs, which drives the quest for highly efficient and cost-effective systems. In discussing expression systems, the primary assumption is that a universal production platform for vaccines and immunotherapeutics will unlikely exist. This review provides an overview of the evolution of traditional expression systems, including mammalian cells, yeast and E.coli, but also alternative systems such as other bacteria than E. coli, transgenic animals, insect cells, plants and microalgae, Tetrahymena thermophila, Leishmania tarentolae, filamentous fungi, cell free systems, and the incorporation of non-natural amino acids.
Collapse
Affiliation(s)
| | - Sophie Buffin
- a Research and Development, Sanofi Pasteur , Marcy L'Etoile , France
| | - Isabelle Peubez
- a Research and Development, Sanofi Pasteur , Marcy L'Etoile , France
| | | | - Régis Sodoyer
- b Technology Research Institute Bioaster , Lyon , France
| | - Bettina Werle
- b Technology Research Institute Bioaster , Lyon , France
| |
Collapse
|
24
|
Castaldo M, Barlind L, Mauritzson F, Wan PT, Snijder HJ. A fast and easy strategy for protein purification using "teabags". Sci Rep 2016; 6:28887. [PMID: 27356497 PMCID: PMC4928122 DOI: 10.1038/srep28887] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2016] [Accepted: 06/07/2016] [Indexed: 12/13/2022] Open
Abstract
Protein purification often involves affinity capture of proteins on stationary resin, alternatively proteins are captured on free flowing resin for subsequent separation from bulk fluid. Both methods require labour and time intensive separation of particulate matter from fluid. We present a method where affinity resin is contained within porous-walled containers, supporting clarification, product recovery, and concentration in a single step with minimal hands-on processing time, without significant investments in equipment.
Collapse
Affiliation(s)
- M Castaldo
- Discovery Sciences, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Pepparedsleden 1, Mölndal, 431 83, Sweden
| | - L Barlind
- Discovery Sciences, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Pepparedsleden 1, Mölndal, 431 83, Sweden
| | - F Mauritzson
- Discovery Sciences, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Pepparedsleden 1, Mölndal, 431 83, Sweden
| | - P T Wan
- Discovery Sciences, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Pepparedsleden 1, Mölndal, 431 83, Sweden
| | - H J Snijder
- Discovery Sciences, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Pepparedsleden 1, Mölndal, 431 83, Sweden
| |
Collapse
|